Galectin Therapeutics to Present at H.C. Wainwright Global Life Sciences Conference

On March 4, 2021 Galectin Therapeutics Inc. (NASDAQ:GALT), the leading developer of therapeutics that target galectin proteins, reported that Dr. Pol Boudes, M.D., Chief Medical Officer, will provide a corporate overview at the upcoming H.C. Wainwright Global Life Sciences Conference to be held March 9-10, 2021 (Press release, Galectin Therapeutics, MAR 4, 2021, View Source [SID1234576112]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation will be available for on-demand listening beginning March 9, 2021 at 7:00 am (EST) and archived for 90 days.

Mustang Bio to Participate in Three March 2021 Virtual Investor Conferences

On March 4, 2021 Mustang Bio, Inc. ("Mustang") (NASDAQ: MBIO), a clinical-stage biopharmaceutical company focused on translating today’s medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors and rare genetic diseases, reported that Mustang’s management team will participate in three virtual investor conferences in March 2021 (Press release, Mustang Bio, MAR 4, 2021, View Source [SID1234576111]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright Global Life Sciences Virtual Conference: The company’s presentation will be available for on-demand viewing on Mustang’s website beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET.
Oppenheimer 31st Annual Virtual Healthcare Conference: The company’s fireside chat will take place on Tuesday, March 16, 2021, at 3:10 p.m. ET.
Redburn Virtual Gene Therapy Summit: The company’s management team will participate in a panel that will take place on Wednesday, March 31, 2021, at 9:15 a.m. ET.
Webcasts of the H.C. Wainwright presentation and Oppenheimer fireside chat will be available on the Events page of the Investor Relations section of Mustang’s website, www.mustangbio.com, for approximately 30 days.

Fortress Biotech to Participate in Four March 2021 Virtual Investor Conferences

On March 4, 2021 Fortress Biotech, Inc. (NASDAQ: FBIO) ("Fortress"), an innovative revenue-generating company focused on acquiring, developing and commercializing or monetizing promising biopharmaceutical products and product candidates cost-effectively, reported that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will participate in four virtual investor conferences in March 2021 (Press release, Fortress Biotech, MAR 4, 2021, View Source [SID1234576110]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

Details of the events are as follows:

H.C. Wainwright Global Life Sciences Virtual Conference: The company’s presentation will be available for on-demand viewing on Fortress’ website beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET and will remain available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the presentation.
Barclays Global Healthcare Virtual Conference: The company will present on Thursday, March 11, 2021, at 3:00 p.m. ET and will participate in one-on-one meetings during the conference.
Virtual 33rd Annual ROTH Conference: The company will participate in a fireside chat on Tuesday, March 16, 2021, at 11:00 AM ET and will attend one-on-one meetings during the conference. A webcast of the fireside chat will be available on the Events page under the News & Media section of Fortress’ website: www.fortressbiotech.com for approximately 30 days following the chat.
Oppenheimer 31st Annual Virtual Healthcare Conference: The company will present on Thursday, March 18, 2021, at 10:40 a.m. ET and will participate in one-on-one meetings during the conference.

Checkpoint Therapeutics to Participate in H.C. Wainwright Global Life Sciences Virtual Conference

On March 4, 2021 Checkpoint Therapeutics, Inc. ("Checkpoint") (NASDAQ: CKPT), a clinical-stage immunotherapy and targeted oncology company, reported that James Oliviero, President and Chief Executive Officer, will participate in the H.C. Wainwright Global Life Sciences Virtual Conference, taking place March 9-10, 2021 (Press release, Checkpoint Therapeutics, MAR 4, 2021, View Source [SID1234576109]). The company’s presentation will be available for on-demand viewing beginning on Tuesday, March 9, 2021, at 7:00 a.m. ET, on the Events page, located within the Investors section of Checkpoint’s website, View Source, for approximately 30 days.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!


HARPOON THERAPEUTICS TO REPORT FOURTH QUARTER 2020 FINANCIAL RESULTS AND PROVIDE CORPORATE UPDATE

On March 4, 2021 Harpoon Therapeutics, Inc. (NASDAQ: HARP), a clinical-stage immunotherapy company developing a novel class of T cell engagers, reported that it will report fourth quarter and full year 2020 financial results and provide a corporate update on Wednesday, March 10, 2021 (Press release, Harpoon Therapeutics, MAR 4, 2021, View Source [SID1234576108]). Harpoon’s management will host a webcast and conference call that day at 4:30 p.m. ET / 1:30 p.m. PT.

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The live call may be accessed by dialing 866-951-6894 for domestic callers and 409-216-0624 for international callers and entering the conference code: 4785099. A live webcast and archive of the call will be available online from the investor relations section of the company website at www.harpoontx.com.